To die or not to die? Current questions in cell death signalling.

Mol Neurobiol

Department of Clinical Neurosciences, University of Edinburgh, Edinburgh, UK.

Published: August 2010

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12035-010-8140-6DOI Listing

Publication Analysis

Top Keywords

die die?
4
die? current
4
current questions
4
questions cell
4
cell death
4
death signalling
4
die
1
current
1
questions
1
cell
1

Similar Publications

Correlation between the severity of endometriosis and the occurrence of placenta accreta spectrum in the subsequent pregnancy.

Pak J Med Sci

January 2025

Shunhe Lin Department of Obstetrics and Gynecology, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology Pediatrics, Fujian Medical University, Fuzhou, Fujian Province 350001, P.R. China.

Objective: To investigate the correlation between endometriosis (EMs) severity and placenta accreta spectrum (PAS) risk in the subsequent pregnancy.

Method: Clinical records of 2,142 patients who underwent laparoscopic surgery for EMs at Fujian Provincial Maternal and Child Health Hospital from January 2014 to January 2018, who had achieved pregnancy and were delivered, were analyzed. Baseline data, EMs stage, The Revised American Fertility Society (R-AFS) score, levels of serum indexes, and pregnancy and neonatal outcomes were recorded.

View Article and Find Full Text PDF

Background: Opioids are frequently prescribed for short-term acute pain following surgery. Used appropriately, opioids deliver extremely favourable pain relief. Used longer than 90-days, however, can result in health complications, including unintentional overdose and addiction.

View Article and Find Full Text PDF

A novel directly compressible co-processed excipient, based-on rice starch for extended-release of tablets.

Eur J Pharm Biopharm

January 2025

Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand; Research Center for Development of Local Lanna Rice and Rice Products, Chiang Mai University, Chiang Mai 50200, Thailand. Electronic address:

The development of a direct compression excipient with extended-release property is crucial for improving tablet manufacturing and drug delivery. This research focuses on developing a novel co-processed excipient composed of rice starch (RS), methylcellulose (MC), and colloidal silicon dioxide (CSD) using a wet granulation technique. The ratios of RS: MC (1.

View Article and Find Full Text PDF

Purpose: Standard therapy for breast cancer after breast-conserving surgery is radiation therapy (RT) plus hormone therapy (HT). For patients with a low-risk of recurrence, there is an interest in deescalating therapy.

Methods And Materials: A retrospective study was carried out for patients treated at the Swedish Cancer Institute from 2000 to 2015, aged 70 years or older, with pT1N0 or pT1NX estrogen receptor-positive and ERBB2-negative unifocal breast cancer without positive surgical margins, high nuclear grade, or lymphovascular invasion.

View Article and Find Full Text PDF

Pseudogenization of the Slc23a4 gene is necessary for the survival of Xdh-deficient mice.

Sci Rep

January 2025

Laboratory of Human Physiology and Pathology, Faculty of Pharmaceutical Sciences, Teikyo University, Tokyo, Japan.

In most patients with type 1 xanthinuria caused by mutations in the xanthine dehydrogenase gene (XDH), no clinical complications, except for urinary stones, are observed. In contrast, all Xdh(- / -) mice die due to renal failure before reaching adulthood at 8 weeks of age. Hypoxanthine or xanthine levels become excessive and thus toxic in Xdh(- / -) mice because enhancing the activity of hypoxanthine phosphoribosyl transferase (HPRT), which is an enzyme that uses hypoxanthine as a substrate, slightly increases the life span of these mice.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!